生物製剤の受託開発市場：供給源、タイプ、適応疾患、フェーズ、サービスタイプ、エンドユーザー別-2025～2030年の世界予測

生物製剤の受託開発市場は、2023年に65億4,000万米ドルと評価され、2024年には73億米ドルに達すると予測され、CAGR 11.79％で成長し、2030年には142億8,000万米ドルに達すると予測されています。

生物製剤の受託開発は、モノクローナル抗体、ワクチン、細胞療法、遺伝子療法を含む生物学的製剤の開発において、バイオテクノロジーおよび製薬企業を支援する専門企業が提供するサービスを包含します。この分野は、生物学的製剤開発に関連する複雑で厳しい規制要件のため、ますます必要性が高まっています。アプリケーションは、細胞株開発、プロセス最適化、スケールアップ生産など様々な段階に及び、バイオ医薬品やバイオテクノロジーなどの産業に対応しています。同市場は、慢性疾患の有病率の上昇、バイオテクノロジーの進歩、個別化医療への関心の高まりによって活性化し、高度な生物学的治療への需要を牽引しています。主な成長要因としては、研究開発活動の活発化、生物製剤開発に対する政府からの旺盛な資金援助、バイオプロセスにおける技術革新などが挙げられます。新たなビジネスチャンスは、プロセスの効率を高め交差汚染を減らすシングルユース技術の採用や、コストに敏感な市場におけるバイオシミラーの需要拡大にあります。

しかし、このような状況に課題がないわけではないです。生物製剤開発に関連する高コスト、熟練した人材の限られた利用可能性、厳格な規制の枠組みなどが市場拡大の妨げとなる可能性があります。さらに、知的財産の問題やスケールアッププロセスの複雑さが大きな障壁となっています。開発プロセスを最適化し、市場投入までの時間を短縮するための人工知能や機械学習の統合といったイノベーションは、事業成長の有望な道筋を示しています。さらに、新規発現系の探索とバイオプロセス効率の向上は、重要な研究とイノベーションの分野となります。市場は競争的かつ断片的な性質を特徴としており、主要企業は戦略的提携、買収、投資に重点を置いてサービス提供の強化と世界の事業拡大を図っています。市場情勢における成長を維持し、新たな動向を捉えるためには、市場機会を活用しようとする企業は、最先端技術への投資、共同事業の育成、規制状況への積極的な対応を行う必要があります。

市場力学：急速に進化する生物製剤の受託開発市場の主要市場インサイトを公開

生物製剤の受託開発市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ワクチンおよびバイオシミラー製造需要の増加
  • 生物製剤活動を奨励する政府の取り組み
  • 生物製剤CDOによる業務効率の向上とコスト削減
• 市場抑制要因
  • エンドユーザーとCDO間のコミュニケーションの問題
• 市場機会
  • 生物製剤開発システムの技術進歩
  • 新たな生物製剤の受託開発サービス拡大への投資
• 市場の課題
  • 知的財産権の侵害に関する懸念

ポーターの5つの力：生物製剤の受託開発市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、生物製剤の受託開発市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：生物製剤の受託開発市場における外部からの影響の把握

外部マクロ環境要因は、生物製剤の受託開発市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析生物製剤の受託開発市場における競合情勢の把握

生物製剤の受託開発市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス生物製剤の受託開発市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、生物製剤の受託開発市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨生物製剤の受託開発市場における成功への道筋を描く

生物製剤の受託開発市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ワクチンとバイオシミラーの生産に対する需要の増加
    • 生物製剤の活動を奨励する政府の取り組み
    • バイオロジクスCDOによる業務効率の向上とコスト削減
  • 抑制要因
    • エンドユーザーとCDO間のコミュニケーションの問題
  • 機会
    • バイオ医薬品開発システムにおける技術の進歩
    • 新しい生物製剤の受託開発サービス拡張への投資
  • 課題
    • 知的財産権侵害に関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 生物製剤の受託開発市場：ソース別

• 哺乳類
• 微生物

第7章 生物製剤の受託開発市場：タイプ別

• 分子療法
• モノクローナル抗体
• 組み換えタンパク質
• ワクチン

第8章 生物製剤の受託開発市場：疾患適応症別

• 心血管疾患
• 血液疾患
• 免疫疾患
• 腫瘍学

第9章 生物製剤の受託開発市場フェーズ別

• フェーズI
• フェーズII
• フェーズIII
• 前臨床

第10章 生物製剤の受託開発市場：サービスタイプ別

• 細胞株の開発
  • 哺乳類
  • 微生物
• プロセス開発
  • 下流
    • 不純物、分離、識別
    • 医薬品分析
    • 物理化学的特性評価
  • 上流
    • 哺乳類
    • 微生物

第11章 生物製剤の受託開発市場：エンドユーザー別

• バイオ医薬品企業
• 調査室

第12章 南北アメリカの生物製剤の受託開発市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の生物製剤の受託開発市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの生物製剤の受託開発市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie, Inc.
• Abzena Ltd.
• Aenova Holding GmbH
• AGC Biologics GmbH
• Avid Bioservices, Inc.
• Binex Co. Limited
• Boehringer Ingelheim International GmbH
• Cambrex Corporation
• Catalent, Inc.
• Emergent BioSolutions, Inc.
• Fujifilm Holdings Corporation
• Icon PLC
• JRS PHARMA GmbH & Co. KG
• JSR Life Sciences, LLC
• Lonza Group AG
• Parexel International Corporation
• ProBioGen AG
• Recipharm AB
• Rentschler Biopharma SE
• Samsung Biologics
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific, Inc.
• Toyobo Co., Ltd.
• WuXi Biologics Inc.

LIST OF FIGURES

• FIGURE 1. BIOLOGICS CONTRACT DEVELOPMENT MARKET RESEARCH PROCESS
• FIGURE 2. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. BIOLOGICS CONTRACT DEVELOPMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. BIOLOGICS CONTRACT DEVELOPMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BIOLOGICS CONTRACT DEVELOPMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BIOLOGICS CONTRACT DEVELOPMENT MARKET DYNAMICS
• TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULAR THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY IMPURITY, ISOLATION, & IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHYSICOCHEMICAL CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 76. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 79. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 80. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 81. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 82. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 83. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 84. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 86. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 93. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 96. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 106. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 117. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 118. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 125. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 126. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 128. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 131. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 132. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 133. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 134. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 135. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 136. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 138. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 141. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 142. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 143. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 144. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 145. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 146. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 148. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 150. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 151. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 153. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 154. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 155. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 156. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 158. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 161. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 163. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 164. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 165. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 166. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 168. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 170. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 171. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 173. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 174. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 175. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 176. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 178. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 181. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 183. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 184. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 185. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 186. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 188. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 190. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 191. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 193. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 194. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 195. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 196. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 197. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 198. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 207. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 208. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 209. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 210. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 211. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 213. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 214. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 215. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 216. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 217. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 218. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 219. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 220. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 221. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 223. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 224. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 225. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 226. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 227. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 228. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 229. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 230. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 231. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 233. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 234. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 235. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 236. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 237. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 238. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 248. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 249. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 250. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 251. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 252. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 253. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 254. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 255. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 256. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 257. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 258. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 259. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 260. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 261. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 262. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 263. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 264. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 265. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 266. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 267. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 268. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 269. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 270. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 271. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 272. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 273. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 274. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 275. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 276. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 277. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 278. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 279. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 280. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 281. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 282. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 283. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 284. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 285. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 286. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 287. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 288. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 289. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 290. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 291. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 292. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 293. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 294. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 295. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 296. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 297. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 298. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 299. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 300. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 301. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 302. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 303. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 304. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 305. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 306. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 307. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 308. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 309. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 310. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 311. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 312. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 313. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (US

The Biologics Contract Development Market was valued at USD 6.54 billion in 2023, expected to reach USD 7.30 billion in 2024, and is projected to grow at a CAGR of 11.79%, to USD 14.28 billion by 2030.

Biologics Contract Development encompasses services provided by specialized companies to assist biotechnology and pharmaceutical firms in the development of biological products, including monoclonal antibodies, vaccines, cell therapies, and gene therapies. This sector is increasingly necessary due to the complexity and stringent regulatory requirements associated with biologic drug development. Applications span across various stages, such as cell line development, process optimization, and scale-up production, catering to industries like biopharmaceuticals and biotechnology. The market is buoyed by the rising prevalence of chronic diseases, advancements in biotechnology, and an increasing focus on personalized medicine, driving the demand for sophisticated biologic therapies. Key growth factors include intensifying research and development activities, robust government funding for biologics development, and technological innovations in bioprocessing. Emerging opportunities lie in the adoption of single-use technologies, which enhance process efficiency and reduce cross-contamination, as well as escalating demand for biosimilars in cost-sensitive markets.

However, the landscape is not without challenges. High costs associated with biologics development, limited availability of skilled personnel, and stringent regulatory frameworks can hinder market expansion. Moreover, intellectual property issues and the complexity of scale-up processes pose significant barriers. Innovations such as the integration of artificial intelligence and machine learning for optimizing development processes and reducing time-to-market present promising avenues for business growth. Additionally, exploring novel expression systems and enhancing bioprocess efficiency provide areas for significant research and innovation. The market is characterized by a competitive and fragmented nature, with key players focusing on strategic partnerships, acquisitions, and investments to enhance their service offerings and expand their global footprint. Companies aiming to capitalize on market opportunities should invest in cutting-edge technologies, foster collaborative ventures, and address regulatory challenges proactively to sustain growth and capture emerging trends in the biologics contract development landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Contract Development Market

The Biologics Contract Development Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing demand for vaccine and biosimilar production
  • Government initiatives encouraging biologics activities
  • Improved operational efficiency and cost saving with biologics CDO
• Market Restraints
  • Communication issues between end-user and CDO
• Market Opportunities
  • Technological advancements in biologics development systems
  • Investments in new biologics contract development services expansion
• Market Challenges
  • Concerns associated with breach of intellectual property

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Contract Development Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Contract Development Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Contract Development Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Contract Development Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Contract Development Market

A detailed market share analysis in the Biologics Contract Development Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Contract Development Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Contract Development Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Contract Development Market

A strategic analysis of the Biologics Contract Development Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Contract Development Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Aenova Holding GmbH, AGC Biologics GmbH, Avid Bioservices, Inc., Binex Co. Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., Fujifilm Holdings Corporation, Icon PLC, JRS PHARMA GmbH & Co. KG, JSR Life Sciences, LLC, Lonza Group AG, Parexel International Corporation, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., Toyobo Co., Ltd., and WuXi Biologics Inc..

Market Segmentation & Coverage

This research report categorizes the Biologics Contract Development Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Source, market is studied across Mammalian and Microbial.
• Based on Type, market is studied across Molecular Therapy, Monoclonal Antibodies, Recombinant Proteins, and Vaccines.
• Based on Disease Indication, market is studied across Cardiovascular Disorders, Hematological Disorders, Immunological Disorders, and Oncology.
• Based on Phase, market is studied across Phase I, Phase II, Phase III, and Preclinical.
• Based on Service Type, market is studied across Cell Line Development and Process Development. The Cell Line Development is further studied across Mammalian and Microbial. The Process Development is further studied across Downstream and Upstream. The Downstream is further studied across Impurity, Isolation, & Identification, Pharmaceutical Analysis, and Physicochemical Characterization. The Upstream is further studied across Mammalian and Microbial.
• Based on End-User, market is studied across Biopharmaceutical Companies and Research Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing demand for vaccine and biosimilar production
    • 5.1.1.2. Government initiatives encouraging biologics activities
    • 5.1.1.3. Improved operational efficiency and cost saving with biologics CDO
  • 5.1.2. Restraints
    • 5.1.2.1. Communication issues between end-user and CDO
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in biologics development systems
    • 5.1.3.2. Investments in new biologics contract development services expansion
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with breach of intellectual property
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Biologics Contract Development Market, by Source

• 6.1. Introduction
• 6.2. Mammalian
• 6.3. Microbial

7. Biologics Contract Development Market, by Type

• 7.1. Introduction
• 7.2. Molecular Therapy
• 7.3. Monoclonal Antibodies
• 7.4. Recombinant Proteins
• 7.5. Vaccines

8. Biologics Contract Development Market, by Disease Indication

• 8.1. Introduction
• 8.2. Cardiovascular Disorders
• 8.3. Hematological Disorders
• 8.4. Immunological Disorders
• 8.5. Oncology

9. Biologics Contract Development Market, by Phase

• 9.1. Introduction
• 9.2. Phase I
• 9.3. Phase II
• 9.4. Phase III
• 9.5. Preclinical

10. Biologics Contract Development Market, by Service Type

• 10.1. Introduction
• 10.2. Cell Line Development
  • 10.2.1. Mammalian
  • 10.2.2. Microbial
• 10.3. Process Development
  • 10.3.1. Downstream
    • 10.3.1.1. Impurity, Isolation, & Identification
    • 10.3.1.2. Pharmaceutical Analysis
    • 10.3.1.3. Physicochemical Characterization
  • 10.3.2. Upstream
    • 10.3.2.1. Mammalian
    • 10.3.2.2. Microbial

11. Biologics Contract Development Market, by End-User

• 11.1. Introduction
• 11.2. Biopharmaceutical Companies
• 11.3. Research Laboratories

12. Americas Biologics Contract Development Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Biologics Contract Development Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Biologics Contract Development Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie, Inc.
• 2. Abzena Ltd.
• 3. Aenova Holding GmbH
• 4. AGC Biologics GmbH
• 5. Avid Bioservices, Inc.
• 6. Binex Co. Limited
• 7. Boehringer Ingelheim International GmbH
• 8. Cambrex Corporation
• 9. Catalent, Inc.
• 10. Emergent BioSolutions, Inc.
• 11. Fujifilm Holdings Corporation
• 12. Icon PLC
• 13. JRS PHARMA GmbH & Co. KG
• 14. JSR Life Sciences, LLC
• 15. Lonza Group AG
• 16. Parexel International Corporation
• 17. ProBioGen AG
• 18. Recipharm AB
• 19. Rentschler Biopharma SE
• 20. Samsung Biologics
• 21. Takeda Pharmaceutical Company Limited
• 22. Thermo Fisher Scientific, Inc.
• 23. Toyobo Co., Ltd.
• 24. WuXi Biologics Inc.